These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35986116)

  • 1. Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Patoulias D; Katsimardou A; Fragakis N; Papadopoulos C; Doumas M
    Acta Diabetol; 2023 Jan; 60(1):1-8. PubMed ID: 35986116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Papadopoulos C; Kassimis G; Fragakis N; Vassilikos V; Karagiannis A; Doumas M
    Vasc Med; 2022 Oct; 27(5):433-439. PubMed ID: 35754338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
    Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Singh AK; Singh R
    Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
    Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F
    Front Public Health; 2021; 9():668368. PubMed ID: 34164370
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
    Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
    Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials.
    Li X; Zhang Q; Zhou X; Guo S; Jiang S; Zhang Y; Zhang R; Dong J; Liao L
    Aging (Albany NY); 2021 May; 13(9):12748-12765. PubMed ID: 33973870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
    Monami M; Liistro F; Scatena A; Nreu B; Mannucci E
    Diabetes Obes Metab; 2018 May; 20(5):1213-1222. PubMed ID: 29327406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.